Net earnings were $842m for the fourth quarter of 2010, compared to $8.35bn for the same period in 2009.
For the full year of 2010, net sales were $19.48bn, compared to $18.81bn for the same period in 2009.
Bristol-Myers CEO Lamberto Andreotti said in the fourth quarter, they delivered solid financial results, concluding a very good year for the company.
"The performance in the quarter is reflective of a year in which robust clinical data, targeted execution of our String of Pearls strategy, and key regulatory submissions provided further proof of our ability to build one of the most innovative pipelines in the industry," Andreotti said.
"In 2011 we will build on the momentum created in 2010. We anticipate several key pipeline events that will help shape our future as we continue to position our company for long-term success as a focused, differentiated BioPharma company."